Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CC-90001
BMS-986360 · 3 trials · 3 indications
Estimation of AUC calculated from time zero to the last measured time point
Estimation of AUC calculated from time zero to infinity
Estimation of observed maximum plasma concentration
Estimation of time to Cmax
Estimation of terminal elimination half-life
Estimation of apparent clearance of drug from plasma after extravascular administration
Estimation of apparent volume of distribution during the terminal phase
Number of subjects with adverse events
Number of subjects experiencing dose interruptions, reductions, and discontinuation of CC-90001 secondary to an AE
Complete Physical Examinations
Heart rate (HR), respiratory rate, blood pressure (BP), and body temperature
| Arm | Type | Description |
|---|---|---|
| BMS-986360 | EXPERIMENTAL | - |
| BMS-986360 + Docetaxel | EXPERIMENTAL | - |
| BMS-986360 + Nivolumab | EXPERIMENTAL | - |
| BMS-986360 + Capecitabine | EXPERIMENTAL | - |
| Administration of CC-90001 | EXPERIMENTAL | Single oral dose of 200 mg of CC-90001 |
| Low dose CC-90001 | EXPERIMENTAL | Low dose (100 mg) CC-90001 administered orally once daily (QD) for 12 continuous weeks |
| High dose CC-90001 | EXPERIMENTAL | High-dose (200 mg) CC-90001 administered orally Once Daily (QD) for 12 continuous weeks |
| Name | Type | Description |
|---|---|---|
| BMS-986360 | DRUG | Specified dose on specified days |
| Docetaxel | DRUG | Specified dose on specified days |
| Nivolumab | DRUG | Specified dose on specified days |
| Capecitabine | DRUG | Specified dose on specified days |
| CC-90001 | DRUG | CC-90001 |
Inclusion Criteria: * Participants in Part 1 must have histologic or cytologic confirmation of non-small cell lung cancer (NSCLC), metastatic triple negative breast cancer (mTNBC), squamous cell carcinoma of head and neck (SCCHN), pancreatic adenocarcinoma (PAAD), renal cell carcinoma (RCC), micros...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BMS-986360 is an investigational small molecule being studied in adults with advanced solid tumors. It is being evaluated both as a single agent and in combination with chemotherapy or nivolumab. It is not approved for any indication and remains in clinical development.
BMS-986360 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is the sponsor of the clinical program evaluating the compound in advanced solid tumors.
BMS-986360 is in Phase 1 clinical development. The single registered trial, NCT05625412, is a Phase 1 study that has been completed. The drug is investigational and has not been approved by the FDA for any use.
BMS-986360 has been studied in one clinical trial, NCT05625412, titled A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors. The Phase 1 trial enrolled 70 participants across the United States, Argentina, Australia, Canada, Chile, France, Italy, Mexico, and Spain, and is completed.
Yes. BMS-986360 is also known as CC-90001, and the two names refer to the same investigational compound. The Phase 1 trial NCT05625412 lists the drug under both designations in its title.
No. BMS-986360 is an investigational drug in Phase 1 clinical development and has not received FDA approval. Its only registered trial, NCT05625412, has been completed, and the compound remains under study for advanced solid tumors.